Multiple Sclerosis Drug Approval Tops SPT Most Read Articles of the Week

Top five most popular articles this week on Specialty Pharmacy Times.

5. Long-Awaited Multiple Sclerosis Drug Wins FDA Approval

Ocrelizumab (Ocrevus) granted FDA approval to treat 2 forms of MS.

https://www.specialtypharmacytimes.com/news/long-awaited-multiple-sclerosis-drug-wins-fda-approval#sthash.X3IBRLSr.dpuf

4. Rheumatoid Arthritis Drug Market Will Reach Nearly $30 Billion by 2025

New report reveals trends in the 8 major markets over the next decade.

https://www.specialtypharmacytimes.com/news/rheumatoid-arthritis-drug-market-will-reach-nearly-30-billion-by-2025#sthash.H9rjndhU.dpuf

3. Dupilumab FDA Approved for Treatment of Atopic Dermatitis

Injection helps clear skin and manage itch severity caused by the disease.

https://www.specialtypharmacytimes.com/news/dupilumab-fda-approved-for-treatment-of-atopic-dermatitis#sthash.DGpUhEc2.dpuf

2. Four Reasons Why Specialty Pharmacies Fail

There is little room for error in the highly competitive specialty pharmacy landscape.

https://www.specialtypharmacytimes.com/news/four-reasons-why-specialty-pharmacies-fail

1.

Ocrelizumab Approval to Shift Multiple Sclerosis Treatment Landscape

Neurologist Michael Racke, MD, discusses the new FDA approval of ocrelizumab and how it will impact the future treatment of MS.

https://www.specialtypharmacytimes.com/news/ocrelizumab-approval-to-shift-multiple-sclerosis-treatment-landscape#sthash.en9uRzFP.dpuf